The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 7, 2007, Pages 908-915

  Diaconu, N C ^a   Kaminska, R ^a   Naukkarinen, A ^b   Harvima, R J ^a   Harvima, Ilkka T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Ctrl Ostrobothnian Central Hospital   (Finland)

Author keywords

Enzyme activity; Inhibition; Serine proteinase; Skin cancer

Indexed keywords

CHYMASE; CHYMASE INHIBITOR; CHYMOTRYPSIN INHIBITOR; PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA ANTIGEN; TRYPTASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BASAL CELL CARCINOMA; CELL ADHESION; CELL COUNT; CELL GRANULE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MAST CELL; PRIORITY JOURNAL; SKIN BIOPSY;

AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, BASAL CELL; CHYMASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; MIDDLE AGED; PROTEASE INHIBITORS; SKIN NEOPLASMS; TRYPTASES;

EID: 34547116870     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.02100.x     Document Type: Article

References (43)

1. Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: For or against tumor growth and metastasis? Anticancer Res 1997; 17: 1541-1550.
2. Aoki M, Pawankar R, Niimi Y, Kawana S. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol 2003; 130: 216-223.
3. Humphreys TR, Monteiro MR, Murphy GF. Mast cells and dendritic cells in basal carcinoma stroma. Dermatol Surg 2000; 26: 200-203.
4. Janowski P, Strzelecki M, Brzezinska-Blaszczyk E, Zalewska A. Computer analysis of normal and basal cell carcinoma mast cells. Med Sci Monit 2001; 7: 260-265.
5. Grimbaldeston MA, Skov L, Baadsgaard O et al. High dermal mast cell prevalence is a predisposing factor for basal cell carcinoma in humans. J Invest Dermatol 2000; 115: 317-320.
6. Grimbaldeston MA, Skov L, Finlay-Jones JJ, Hart PH. Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans. Methods 2002; 28: 90-96.
7. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol 2006; 19: 149-159.
8. TC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989; 7: 1509-1515.
9. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites: Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Path Res Pract 1993; 189: 156-162.
10. Briggaman RA, Schechter NM, Fräki JE, Lazarus GS. Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes. J Exp Med 1984; 160: 1027-1042.
11. Kaminska R, Helisalmi P, Harvima RJ et al. Focal dermal-epidermal separation and fibronectin cleavage in basement membrane by human mast cell tryptase. J Invest Dermatol 1999; 113: 567-573.
12. Huttunen M, Harvima IT. Mast cell tryptase and chymase in chronic leg ulcers: Chymase is potentially destructive to epithelium and is controlled by protease inhibitors. Br J Dermatol 2005; 152: 1149-1160.
13. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72000 dalton gelatinase and fibronectin. J Cell Biochem 1992; 50: 337-349.
14. Lazaar AL, Plotnick MI, Kucich U et al. Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells. J Immunol 2002; 169: 1014-1020.
15. 84 bond by mast cell chymase. J Biol Chem 1994; 269: 18134-18140.
16. Gruber BL, Marchese MJ, Suzuki K et al. Synovial procollagenase activation by human mast cell tryptase: Dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657-1662.
17. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994; 269: 9416-9419.
18. Abe M, Kurosawa M, Ishikawa O, Miyachi Y, Kido H. Mast cell tryptase stimulates both human dermal fibroblast proliferation and type I collagen production. Clin Exp Allergy 1998; 28: 1509-1517.
19. Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest 1997; 99: 1313-1321.
20. Blair RJ, Meng H, Marchese MJ et al. Human mast cells stimulate vascular tube formation: Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-2700.
21. Kofford MW, Schwartz LB, Schechter NM et al. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem 1997; 272: 7127-7131.
22. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689-4696.
23. Strik MCM, Wolbink A, Wouters D et al. Intracellular SERPINB6 (P16) is abundantly expressed by human mast cells and forms complexes with β-tryptase monomers. Blood 2004; 103: 2710-2717.
24. Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Current Pharm Design 1998; 4: 381-396.
25. Schechter NM, Sprows JL, Schoenberger OL et al. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989; 264: 21308-21315.
26. Walter M, Sutton RM, Schechter NM. Highly efficient inhibition of human chymase by α (2)-macroglobulin. Arch Biochem Biophys 1999; 368: 276-284.
27. Schick C, Kamachi Y, Bartuski AJ et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem 1997; 272: 1849-1855.
28. Harvima IT, Naukkarinen A, Paukkonen K et al. Mast cell tryptase and chymase in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285: 184-192.
29. Kaminska R, Naukkarinen A, Glinski W, Horsmanheimo M, Harvima IT. Mast cells in developing subepidermal bullous diseases: Emphasis on tryptase, chymase and protease inhibitors. Acta Derm Venereol (Stockh) 1999; 79: 351-355.
30. Huttunen M, Aalto M-L, Harvima RJ, Horsmanheimo M, Harvima IT. Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds. Exp Dermatol 2000; 9: 258-265.
31. Riekki R, Harvima IT, Jukkola A, Risteli J, Oikarinen A. The production of collagen and the activity of mast-cell chymase increase in human skin after irradiation therapy. Exp Dermatol 2004; 13: 364-371.
32. Kankkunen JP, Harvima IT, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 1997; 72: 385-388.
33. Iamaroon A, Pongsiriwet S, Jittidecharaks S et al. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med 2003; 32: 195-199.
34. Ribatti D, Vacca A, Ria R et al. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003; 39: 666-674.
35. Yamamoto T, Katayama I, Nishioka K. Expression of stem cell factor in basal cell carcinoma. Br J Dermatol 1997; 137: 709-713.
36. Kaminska R, Harvima IT, Naukkarinen A, Nilsson G, Horsmanheimo M. Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection. J Pathol 1996; 180: 434-440.
37. Kivinen PK, Kaminska R, Naukkarinen A et al. Release of soluble tryptase but only minor amounts of chymase activity from cutaneous mast cells. Exp Dermatol 2001; 10: 246-255.
38. Kivinen PK, Nilsson G, Naukkarinen A, Harvima IT. Mast cell survival and apoptosis in organ-cultured human skin. Exp Dermatol 2003; 12: 53-60.
39. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin. Clin Exp Allergy 2001; 31: 593-601.
40. Harvima IT, Haapanen L, Ackermann L et al. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. Acta Derm Venereol (Stockh) 1999; 79: 98-104.
41. Westin U, Polling Å, Ljungkrantz I, Ohlsson K. Identification of secretory leukocyte protease inhibitor (SLPI) in human mast cells using immunohistochemistry and in situ hybridisation. Biol Chem 1999; 380: 489-493.
42. Ide H, Itoh H, Yoshida E et al. Immunohistochemical demonstration of inter-α-trypsin inhibitor light chain (bikunin) in human mast cells. Cell Tissue Res 1999; 297: 149-154.
43. Takeda A, Higuchi D, Takahashi T et al. Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J Invest Dermatol 2002; 118: 147-154.